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ABSTRACT
miRNAs are promising biomarkers but methods 
for their measurement are not clear. We therefore 
examined three miRNA detection technologies and 
considered the analytical characteristics essential 
for clinical utilization. TaqMan assays, SplintR-qPCR 
and miREIA were compared for their absolute quanti-
fication bias, conformity and robustness. Absolute 
concentrations of miR-142-5p, miR-23a-3p and 
miR-93-5p were measured with all three methods 
using 30 samples. Robustness was evaluated by 
measurement of miR-21-5p in five uniform experi-
ments. Correlations were miRNA-specific, but we 
observed a different absolute concentration range 
in RT-qPCR (fmol/μl) and methods evading the RT 
process (amol/μl). Consistently, RT-less methods 
reported better robustness (CV 8–19%) than RT-qPCR 
(CV 39–50%). The calibration curve in TaqMan 
Advanced assay was influenced by dilution media. 
Methods avoiding RT seem to be a promising future 
alternative for miRNA measurement.
METHOD SUMMARY
Three miRNA detection technologies were compared: 
1) RT-qPCR where the RT step was performed with 
either a specific (TaqMan miRNA assay) or universal 
(TaqMan Advanced assay) priming strategy; 2) 
miREIA technology, using hybridization and specific 
antibody to DNA/RNA hybrids and 3) SplintR-qPCR, 
which utilizes a hybridization and ligation step 
followed by qPCR.
miRNAs are small noncoding RNA 
molecules that play an important 
regulatory role in gene translation 
through silencing or degradation of 
target mRNAs [1]. They influence a 
wide range of major biological 
processes including differentiation, 
proliferation, metabolism, apoptosis 
or inflammation [2–5]. Deregulation 
of miRNA levels within cells is 
associated with various diseases, so 
they have an immense potential to 
serve as diagnostic or prognostic 
biomarkers [6]. Utilization of circu-
lating miRNA as a noninvasive 
diagnostic tool in liquid biopsies is 
also very promising [7].
However, precise detection 
and quantification of miRNA is 
challenging and limits further 
miRNA research. Therefore, there is 
a need for a reliable miRNA detection 
platform that could be used routinely 
in laboratories. Problematic determi-
nation of miRNAs in the sample is 
caused by the short length of these 
molecules (approximately 22 nucle-
otides), small sequence differences 
between miRNAs and also their low 
concentrations in body fluids [8]. 
Nevertheless, many approaches for 
detecting miRNA have been intro-
duced. The most common are RNA 
sequencing (RNA-Seq), microarrays 
and reverse transcription PCRs 
(RT-qPCR) [9].
RNA-Seq utilizes NGS for high-
throughput analysis of miRNA. The 
most widespread NGS technology 
is based on individual binding of 
fluorescent-labeled nucleotides. 
This approach can determine many 
heterogeneous samples in one 
run and simultaneously provides 
sequence information for each 
miRNA contained in the sample. NGS, 
as the only method, can be used to 
discover new miRNA molecules and 
is also the most sensitive principle 
for miRNA identification and quanti-
fication. On the other hand, NGS is 
very time-consuming, because 
extensive processing steps are 
required to convert a sample into a 
library for sequencing. High volume 
of sample is consumed in this 
process and sophisticated software 
is required for evaluating results. The 
combination of expensive chemistry 
and instrumentation means a high 
cost per analysis [10].
Microarray is used for multiplex 
analysis of already described 
miRNAs. The central concept is 
based on hybridization of the target 
with a specific probe to measure 
the abundance of nucleic acid 
sequences through fluorescence-
based detection [11]. Many different 
probes are usually bound on a solid 
surface and thus miRNA expression 
chips with hundreds of targets are 
created. Chips are commercially 
available with preselected targets 
or can be tailored to the customer’s 
needs [9]. In principle, microarrays 
can provide very precise information 
about absolute concentration of 
miRNA. However, in practice, there 
is huge quantification bias due 
to unreliable background correc-
tions and normalization, so they 
are usually considered for relative 
quantification only. The sensitivity 
of microarray is lower than RNA-seq 
because there is no amplification 
step. Measurement is also limited 
by the sensitivity of the fluores-
cence reader, so expensive instru-
mentation is required [9,11].
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NGS and microarrays together are 
probably not suitable for routine utili-
zation; their strength lies in the discovery 
of new miRNAs and the search for differ-
ential miRNA expression connected to 
pathological conditions. The one with the 
biggest potential for diagnostic purposes 
is the gold-standard RT-qPCR [9].
For detection of short RNA molecules 
(including miRNA), adaptions of the 
standard RT-qPCR techniques have been 
established and they are currently the 
most widely used [12]. PCR is preceded 
by enzymatic transformation of mature 
miRNA into a cDNA sequence and then 
amplification of this sequence by appro-
priate primers [13]. The most error-prone 
step of the process is the RT reaction, 
which can be performed in two ways. The 
first method uses specific stem-loop RT 
primers to produce cDNA from specific 
miRNA. The primer hybridizes to the 3′ 
section of the miRNA while at the same 
time prolonging the 3′ end of the molecule 
with its 5′ end to generate a nicked RNA 
hybrid of miRNA and stem-loop primer. 
After RT, the resulting cDNA is amplified 
by qPCR using a forward primer specific to 
the miRNA sequence and a reverse primer 
specific to the stem-loop primer [14,15]. The 
second method extends the miRNA at its 
3′ end with a poly(A) tail by using enzyme 
poly(A) polymerase. The resulting polyad-
enylated RNA is then reverse transcribed 
using a universal oligo(dT) primer, therefore 
all miRNAs within the RNA sample are 
transcribed [12,14,16,17]. Following 
measurement of selected miRNAs, specific 
PCR primers are used for amplification of 
reverse transcribed cDNA [14,17].
As RT-qPCR techniques can be 
performed on relatively standard 
equipment, these tests are widely available 
and can be automated. Sensitivity, speci-
ficity and reproducibility of RT-qPCR is 
generally considered as very good, but an 
undeniable bias of the RT process is often 
overlooked. This technology is useable only 
for molecules that have been previously 
identified, but despite its imperfections 
in comparison with the above-mentioned 
techniques it is the most attractive one for 
routine testing in clinical laboratories [14].
Never theless, other promising 
approaches for miRNA detection have 
recently been presented. The first approach 
preserves qPCR as the visualization system 
but innovates the process of cDNA synthesis. 
RT is replaced by enzymatic ligation of two 
DNA oligonucleotides splinted by target 
miRNA. Because ligation of single-strand 
breaks in DNA/RNA hybrids is not usual in 
living organisms, success of this technology 
consists requires a suitable ligation enzyme. 
Only recently, Chlorella virus DNA ligase 
(SplintR ligase) has been found, which 
is able to catalyze such a reaction with 
sufficient efficacy for miRNA detection. 
Multiple miRNAs have already been deter-
mined by SplintR-qPCR using a double-
quenched TaqMan probe. Only a 4–6 bp 
overlap between a DNA probe and miRNA 
was required for efficient ligation, providing 
more flexibility in probe design and allowing 
it to reach higher specificity [18].
The second approach utilizes the 
properties of a unique monoclonal antibody 
specific only to perfectly matched DNA/RNA 
hybrids. This system was introduced in 2015 
by Kappel et al. and later was transformed 
to the format of a classical immunoassay 
named miREIA (miRNA enzyme immuno-
assay) [19]. This method does not involve 
RT nor amplification. The protocol is based 
on hybridization of a DNA probe to the 
miRNA target and followed by the subse-
quent quantification of generated DNA/
RNA hybrids. The workflow is very similar 
to the well-known ELISA principle, which is 
convenient for clinical laboratory settings. 
Moreover, this system is also applicable for 
standard immunoanalyzers and allows for 
multiplex measurement [19].
Although the technologies mentioned 
above could provide solutions for miRNA 
measurement, there is still a need for more 
data focused on their analytical character-
istics. In this study we compared RT-qPCR, 
SplintR-qPCR and miREIA detection 
methods for their analytical characteristics 
necessary for clinical utilization.
MATERIALS & METHODS
Synthetic oligonucleotides
RNA oligonucleotides and DNA primers were 
synthetized by Eurofins genomics. 
Sequences of the miRNA oligonucleotides 
were obtained from miRbase Release 21 
(www.mirbase.org).
Probes & primers sequences for 
SplintR-qPCR
Probe A23: 5′ CCTCTCTATGGGCAGTCGGT-
GAGGAAATCCCT 3′
Probe B23: 5′ PHO-GGCAATGTGATT-
GAGTCGGGAGACACGCAGGG 3′
Probe A93: 5′ CCTCTCTATGGGCAGTCG-
GTGACTACCTGCACG 3′
Probe B93: 5′ PHO-AACAGCACTTTGT-
GAGTCGGGAGACACGCAGGG 3′
Probe A142: 5′ CCTCTCTATGGGCAGTCG-
GTGACGTAGTGCTT 3′
Probe B142: 5′ PHO-TCTACTTTATGT-
GAGTCGGGAGACACGCAGGG 3′
Probe A21: 5′ CCTCTCTATGGGCAGTCG-
GTGATCAACATCAG 3′
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Probe B21: 5′ PHO-TCTGATAAGCTAT-
GAGTCGGGAGACACGCAGGG 3′
Forward primer: 5′ GCTCGACCTCTC-
TATGGGC 3′
Reverse primer: 5′ TTAAGCCCTGCGT-
GTCTCC 3′
Samples & RNA isolation
A total of 19 samples of whole blood and 
11 samples of peripheral blood mononu-
clear cells (PBMCs) were used in this 
study. All 30 samples were provided by 
healthy volunteers. 2.5 ml of whole blood 
was collected in PAXgene Blood RNA 
Tubes (Preanalytics) and handled 
according to manufacturer’s instructions. 
For obtaining the PBMC layer, 5 ml of 
blood was collected in EDTA tubes 
(Vacutainer System BD) and overlaid to 
10 ml of Histopaque (Sigma Aldrich). 
PBMCs were then separated by gradient 
centrifugation.
Total RNA including miRNA was purified 
manually with miRNeasy Mini Kit (Qiagen). 
Briefly, tubes were thawed for 2 h at room 
temperature and then centrifuged for 
10 min at 4500x g. The supernatant was 
removed immediately, and the pellets were 
resuspended in 4 ml RNase-free water 
and centrifugated again. 500 μl of QIAzol 
solution (Qiagen) was added to obtained 
pellets. Then, the isolation proceeded 
according to the manufacturer’s recom-
mendations. The total elution volume was 
50 μl of RNAse-free H2O. Quality of isolated 
RNA was determined using Nanodrop 
ND-2000 (ThermoFisher Scientific). The 
ratio of absorbance at 260/280 nm was 
1.95–2.13 for all samples. Isolated RNA 
was stored at −80°C until use.
miRNA detection
RT-qPCR was performed using TaqMan 
miRNA assays or TaqMan Advanced assays 
(both Thermofisher Scientific) according to 
manufacturer’s instructions. 10 ng of total 
RNA was used as an input amount for cDNA 
synthesis. All calibration curves were done 
using synthetic RNA, by ten-times serial 
dilutions of the RT product. Reactions were 
performed in CFX96 real-time detection 
system (BioRad) and results were evaluated 
with related software (BioRad).
The SplintR-qPCR procedure was 
obtained from Jin et al. [18] and modified 
in-house. The hybridization mix was 
composed of: 1 μl of probe A (1 pmol/μl); 
1 μl of probe B (1 pmol/μl), 2 μl of hybrid-
ization buffer (1% triton X-100, 10% BSA, 
50% tris-buffered saline), 0.02 μl of RNAse 
inhibitor (Sigma Aldrich) and 4.98 μl of 
nuclease-free water. 1 μl of undiluted 
sample was added to the total reaction 
volume of 10 μl. Hybridization reactions 
were incubated for 3 min at 4°C, 2 min at 
85°C and 5 min at 37°C. The ligation step 
was performed using 1 μl of SplintR ligase 
(New England Biolabs), 2 μl of ligation 
buffer (New England Biolabs) and 15 μl of 
nuclease-free water. 2 μl of hybridization 
product was added to the total volume of 
20 μl. Tubes were incubated for 15 min at 
25°C, 5 min at 4°C, and 10 min at 65°C to 
ligate the product and then held at 4°C. 
qPCR was performed in the final volume 
of 20 μl using 0.5 μl of forward and reverse 
primer (10 μM), 10 μl of IQ Syber Green 
supermix (BioRad), 7 μl of nuclease-free 
water and 2 μl ligation product (ten-times 
diluted). The qPCR protocol was as follows: 
95°C for 3 min and 45 cycles of 95°C for 10 
s, 55°C for 20 s and 72°C for 1 s. Reaction 
specificity was assessed by melting curve 
analysis immediately after the qPCR. All 
incubation and amplification steps were 
done in the CFX96 real-time detection 
system (BioRad). Results were evaluated 
with related software. All calibration curves 
were constructed by ten-times serial 
dilution of ligation product.
miREIA (BioVendor – Laboratorní 
medicína) measurement was done 
according to manufacturer’s instruc-
tions. Samples were diluted at least 
five times. All calibration curves were 
constructed according to the product data 
sheet. Hybridization was done in peqStar 
thermocycler (Peqlab). All reactions were 
incubated in Incucell (BMT) incubator and 
absorbance was measured in a 96-well 
reader EL808 (Biotek). Sample concentra-
tions were calculated with GEN software.
Analytical characteristics of miRNA 
detection methods
Correlation of TaqMan miRNA assays, 
SplintR-qPCR and miREIA was determined 
for miR-142-5p, miR-23a-3p and miR-93-5p. 
Absolute concentrations of all miRNA 
targets were measured in 19 whole-blood 
and 11 PBMC samples. Synthetic miRNAs 
were used to generate standard curves. All 
experiments were done in duplicate.
Influence of different dilution media 
for standard curve preparation was 
evaluated for miR-142-5p. Synthetic RNA 
was diluted in nuclease-free water, a 
cocktail of nonsense miRNAs (1000 fmol/
μl; miR-208a-3p, miR-376c-3p, miR-126-5p, 
miR-197-3p, miR-222-3p) and yeast RNA 
(5 ng/μl, Thermofisher Scientific). For the 
TaqMan miRNA and TaqMan Advanced 
assays, synthetic RNA was diluted to 
obtain a final concentration of miR-142-5p 
1000 fmol/μl and 7 ng of total RNA was 
used as an input amount. Hybridization 
is not prone to changes in the total RNA 
amount, so nonsense miRNA and yeast 
RNA was used instead of water solvent 
in SplintR-qPCR and miREIA protocols. 
Starting concentration for SplintR-qPCR 
was 100 fmol/μl and for miREIA 12.5 amol/
μl of synthetic miR-142-5p. Shifts in Cq 
and absorbance values, respectively, 
were evaluated between different dilution 
media.
Robustness of the methods (TaqMan 
miRNA assays, SplintR-qPCR and miREIA) 
was assessed in one whole-blood and 
one PBMC RNA isolate. Samples were 
aliquoted and stored at −80°C to avoid 
repeated freezing–thawing cycles. 
Absolute concentration of miR-21-5p was 
determined using standard curve. Results 
obtained by uniform measurement over 5 
distinct days were used to calculate the CV 
for each sample. Each measurement was 
done in two replicates. CV was calculated 
according to the formula:
(SDc: Standard deviation of concentration 
values; Øc: Average of concentration values)
RESULTS & DISCUSSION
The mandatory requirement of the EU for 
use of any type of diagnostic test in the 
routine lab is CE-IVD certification. In this 
process, predefined analytical character-
istics (including robustness, specificity, 
sensitivity, etc.) of the diagnostic test have 
to meet some expected criteria to pass the 
certification. This rule will not avoid the 
oncoming clinical use of miRNA molecules.
It is important to realize that the 
demanding characteristics of the CE-IVD 
test are influenced not only by the power 
of the biomarker itself, but also by the 
Reports
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measurement technology chosen for 
biomarker detection. Contrary to this, 
especially in world of miRNA molecules, 
this issue does not pay much attention 
and necessary analytical character-
istics of miRNA detection methods are 
not being tested. Therefore, we evaluated 
three miRNA detection technologies 
that are based on different principles: 
(1) well-known RT-qPCR, RT step is 
based on using specific (TaqMan 
miRNA assay) or universal (TaqMan 
ADVANCED assay) priming strategy; 
(2)miREIA technology, using hybridization 
and specific antibody to DNA/RNA 
hybrids [19]; (3)SplintR-qPCR, a combination 
of the previously mentioned methods, which 
utilizes a hybridization and ligation step 
followed by qPCR [18].
There are many studies that focus on 
the sensitivity and specificity of RT-qPCR 
methods. Generally, using a specific priming 
strategy is usually more specific, but less 
sensitive. By contrast, the universal RT 
priming strategy is more sensitive, but 
generates higher background [20]. Little 
information regarding specificity and sensi-
tivity is available regarding miREIA and 
SplintR-qPCR because they are new and less 
common. Based on our experiments we can 
claim that these methods are less sensitive 
than RT-qPCR. In most cases, we were not 
able to detect miRNA in serum or plasma 
samples (data not shown). Another disad-
vantage of hybridization-based methods is 
their lower dynamic range and for miREIA 
technology there is also higher sample 
consumption. However, in clinical applica-
tions it is also necessary to evaluate another 
important characteristic of the assays – 
absolute quantification, which makes it 
possible to compare results obtained by 
different laboratories, and also robustness 
and accuracy of the methods. Therefore, 
those performance parameters were inves-
tigated in this study.
Influence of dilution media on synthetic 
calibration curves
The construction of a proper calibration 
curve is the first step for reliable absolute 
quantification, but this remains a challenging 
topic in RT-qPCR methods. The most crucial 
step is to ensure the same efficiency of RT 
in the sample and the synthetic material 
used for generating the calibration curve. 
Usually, some background RNA is recom-
mended to dissolve the standard 
material [21]. We wanted to examine how 
crucial it is in our miRNA detection methods.
The influence of background RNA on 
the miRNA standard curve preparation was 
evaluated by serial dilution of synthetic 
miR-142-5p in different dilution media. We 
used yeast RNA, which is recommended 
by the MIQE guidelines [22], cocktail of 
nonsense miRNA to mimic isolation only 
short RNA from the sample and compared 
it with the miRNA dissolved in nuclease-free 
water, which is the most commonly used 
solvent. We observed no significant media 
influence in singleplex RT-qPCR (Figure 1A) 
nor in methods without RT (miREIA and 
SplintR-qPCR) (Figure 1C & D). On the other 
hand, we have shown a significant Cq shift in 
the calibration curves determined by TaqMan 
Advanced qPCR method (Figure 1B). The 
average Cq shift was 5.6 between the same 
concentration of synthetic RNA dissolved 
in water and a cocktail of nonsense miRNA 
and 2.3 between water and yeast RNA. As a 
consequence, different preparations of the 
synthetic calibration curve with this method 
could dramatically influence the absolute 
concentration of miRNA in the sample.
TaqMan Advanced assay utilizes the 
universal conversion of all miRNA in the 
sample. In all cases, the same amount 
of total RNA and the same concen-
tration of standard RNA material was 
used for RT, so the requirements for RT 
were maintained. However, different total 
amounts of standard miRNA were present 
in the sample. When assuming the same 
efficiency of universal primers and reverse 
transcriptase in the RT reaction, a different 
amount of standard miRNA can be trans-
formed to the form of cDNA, which could 
-3 -2
C
q
-1 0
Log (concentration amol/µl)
TaqMan Advanced – calibration curves
1 2 3 4
15
10
5
20
25
30
35
Water Nonsense miRNA Yeast RNA
Yeast RNANonsense miRNAWater
-3 -2
C
q
-1 0
Log (concentration amol/µl)
TaqMan miRNA assay – calibration curves
1 2 3 4
10
5
15
20
25
30
Water Nonsense miRNA Yeast RNA
Yeast RNANonsense miRNAWater
Figure 1. Comparison of synthetic calibration curves of miR-142-5p dissolved in different dilution 
media (blue – water, orange – nonsense miRNA, grey – yeast RNA). Measured by (A) RT-qPCR,  
(B) RT-qPCR ADVANCED, (C) SplintR-qPCR and (D) miREIA.
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cause Cq shift [23]. This universal RT 
principle used in the TaqMan Advanced 
assay was therefore inappropriate for 
calibration curve preparation and for that 
reason was excluded from the c orrelation 
and robustness experiments.
Correlation of methods
Correlation and absolute concentration 
experiments were determined for TaqMan 
miRNA assay, SplintR-qPCR and miREIA. 
30 RNA isolates from whole blood and 
PBMCs were measured for three miRNA 
targets – miR-142-5p, miR-23a-3p and 
miR-93-5p. Those targets were published 
previously as important candidate markers 
for early diagnosis of colorectal cancer [24].
Individual correlation patterns were 
miRNA- and assay-specific. For miR-142-5p 
we found a strong correlation between 
SplintR-qPCR and miREIA (R2 = 0.883; 
Figure 2A) and marginal c orrelation 
between RT-qPCR and the other methods 
(R2 = 0.501 and 0.493; Figure 2B & C). 
A similar pattern was also observed 
for miR-93-5p. A very high correlation 
coefficient was found between SplintR-
qPCR and miREIA (R2 = 0.792; Figure 2D) 
and also for SplintR-qPCR and RT-qPCR 
(R2 = 0.699; Figure 2E) and lower corre-
lation for miREIA and RT-qPCR (R2 = 0.567; 
Figure 2F). A different pattern was shown 
for miR-23a-3p. Good correlation was 
observed for SplintR-qPCR and RT-qPCR 
(R2 = 0.686; Figure 2H), but only weak corre-
lation of miREIA with either qPCR methods 
(R2 = 0.236 and 0.231; Figure 2G & I) was 
found.
Despite correlations, the most 
problematic miRNA was miR-23a-3p. Unlike 
miR-142-5p and miR-93-5p, this miR-23a-3p 
is a member of a larger family that also 
includes miR-23b and miR-23c (www.
mirbase.org). Measurement of a miRNA 
that has another sibling is always more 
complicated in terms of specificity [25]. 
This could cause greater variation in 
measurements by different technologies 
and, as a consequence, lower correlation 
results [26]. Measurement of miR-142-5p, 
miR-93-5p and also miR-21-5p (Table 1) 
supports the previously indicated fact 
that the RT step causes most of the 
variability produced in RT-qPCR [27], and 
this variability is higher with RNA with a 
shorter length of template [28]. Although 
RT-qPCR is the most commonly used 
technology in research [23], results are 
usually evaluated as relative difference 
between two compared groups. Surpris-
ingly, only a minority of studies have 
focused on absolute quantification of 
miRNA by RT-qPCR [29–31]. Unfortunately, 
we were not able to compare our data with 
these independent studies.
Determination of absolute  
concentration
Generally, we observed absolute concen-
tration conformity in the methods that 
evaded the RT process and three logs shift 
in the concentrations measured by 
RT-qPCR; determined concentration by 
RT-qPCR was approximately 1000-times 
higher. This shift was approximately 
constant across all measured targets and 
samples. One possible cause of the 
observed phenomenon is the RT step itself. 
RT is generally considered to be the most 
problematic step in RT-qPCR [32]. The 
efficiency of conversion of miRNA to cDNA 
strongly depends on the input amount of 
RNA, priming strategy [27,33], template 
concentrations and background RNA in the 
sample [34]. Influence of these factors can 
be reduced by careful assay design. 
However, miRNA molecules are only 19–23 
nucleotides long and very similar in 
sequence, making the specific RT-primer 
design very complicated [8]. This finding 
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Figure 1 (cont.). Comparison of synthetic calibration curves of miR-142-5p dissolved in different 
dilution media (blue – water, orange – nonsense miRNA, grey – yeast RNA). Measured by (A) 
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favors methods evading the RT step and 
supports the hypothesis that hybridization 
of a specific probe to miRNA is less sensitive 
to concentration changes of total RNA, or 
the presence of organic contaminants.
Robustness
To evaluate robustness of absolute quanti-
fication of RT-qPCR, SplintR-qPCR and 
miREIA we used two samples and 
measured the absolute concentration of 
miR-21-5p over 5 days. Results are shown 
in Table 1. The best robustness was 
observed for miREIA technology; CV was 
determined to be 17 and 8% for whole-blood 
and PBMC samples, respectively. Very 
similar results were obtained for SplintR-
qPCR (CV = 19 and 16%, respectively). Using 
these two methods we also reached accor-
dance in absolute concentration of 
miR-21-5p. RT-qPCR exhibited the worst 
robustness of the methods tested: CV was 
determined to be 39 and 50% for whole-
blood and PBMC samples, respectively. 
Also, the concentration of miR-21-5p deter-
mined by RT-qPCR was 1000 times higher 
than values determined by the other 
methods (as discussed above).
Using methods evading RT turned out 
to be beneficial for the robustness of the 
assay. RT has been reported to be a highly 
variable step in the RT-qPCR procedure [27]. 
On the other hand, this method has also 
been reported to be very robust with low 
CVs [35]. In this case we have to consider 
that the results were generated in Cq units 
and these units are logarithmic, not linear. If 
the CV is calculated based on the levels of 
Cq values, it will be much higher in the level 
of absolute concentration. These results 
are consistent with data published previ-
ously, where CVs of TaqMan miRNA and 
Exiqon assays were determined based on 
three independent measurements [30]. 
CV for miR-21-5p was determined to be 
8.15 to 33.66%, and CVs for other miRNA 
targets varied from 10 to 60% [29]. We think 
this is serious problem. Previous studies 
have reported significant d ifferences in 
relative miRNA expression of as low as 
1.5-fold [36–38], but our findings suggest that 
such small differences in expression should 
be treated with caution because of a large 
deviation in repeated measurements [29]. 
Even if these differences were measured 
reliably, due to the high CV observed with the 
qPCR method it is not possible to clinically 
validate these small differences detected by 
RT-qPCR technology. With this last point we 
can see the biggest advantage of miREIA 
technology. It is very similar to ELISA kits 
that are commonly used and also has very 
similar properties, including robustness, 
making it likely to meet the demanding 
criteria of clinical validation.
CONCLUSION
In the last few decades, miRNA molecules 
dramatically increased their potential to 
serve as routine laboratory biomarkers due 
in part to the increasing number of clinical 
studies. However, miRNAs can only reach 
their full potential if the detection procedures 
are properly characterized. In our study, we 
evaluated methods of miRNA detection for 
analytical characteristics necessary for 
clinical utilization. Based on our results, 
RT-qPCR is the least appropriate. On the 
Table 1. Robustness of RT-qPCR, SplintR-qPCR and miREIA. miR-21-5p was determined in two samples on 5 
distinct days.
  RT-qPCR SplintR-qPCR miREIA
  Concentration (fmol/µl) SD CV (%)
Concentration 
(amol/ul) SD CV (%)
Concentration 
(amol/µl) SD CV (%)
Whole blood 7.4 2.9 39 19.1 3.6 19 18.2 3.1 17
Peripheral blood mononuclear cell 10.2 5.1 50 64.8 10.4 16 54.1 4.2 8
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Figure 2. Correlations of absolute concentrations determined in 30 samples by TaqMan 
miRNA assays, SplintR-qPCR and miREIA. (A, B, C) miR-142-5p, (D, E, F) miR-93-5p and (G, H, I) 
miR-23a-3p.
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other hand, it remains the most sensitive 
method and definitely has a place in miRNA 
measurement. SplintR-qPCR and miREIA 
technologies are more robust and absolute 
quantification is more precise. They are 
suitable for clinical laboratories measuring 
samples from tissues and whole blood, but 
there has to be some development work 
carried out in terms of sensitivity, because 
plasma and serum samples are still the most 
common sample types being used.
FUTURE PERSPECTIVE
miRNAs and their detection and 
measurement are currently one of the most 
discussed topics across the scientific 
community, so a future increase in number 
of studies – including clinical ones – 
focused on miRNA is highly probable. It is 
inevitable that there will be development of 
correct and reliable methods for miRNA 
measurement. In the near future there will 
be a great effort to move miRNA biomarkers 
into clinical practice, so the methods will be 
optimized according to clinical laboratory 
requirements. We expect increased attention 
to the field of analytical performance of 
current detection technologies.
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